This work note is a summary of the professional high-end business of financial professionals in China and the world's major financial markets, and does not represent the opinions of any organization. This session was hosted by Professor Ba Shusong, and Ms. Zhao Ying gave a speech. This session mainly explains the trends and opportunities for cross-border investment in China's large health sector. The data shows that the return on investment in the big health sector in the global secondary market is outstanding, and the yield of the pharmaceutical sector in China is also significantly higher than the overall market yield. Under the influence of driving factors such as the rapid development of market capacity, China has triggered a boom in cross-border investment. In this context, there are opportunities for cross-border investment in China's large health sector.

one. Why choose a big health field?

(1) Great health field: outstanding return on investment

In the global secondary market, the return on investment in the big health sector is the highest, exceeding all other sectors.

深度解析:中国大健康领域投资趋势与机遇

In the secondary market in China, the average yield of the pharmaceutical sector is also significantly higher than the comprehensive rate of return.

深度解析:中国大健康领域投资趋势与机遇

In the primary and secondary markets of the United States, returns in the big health sector are significantly higher than the overall market average. In the primary market, the returns of all sub-sectors of great health are higher than the overall average of the primary market.

深度解析:中国大健康领域投资趋势与机遇

(2) Great health area: strong driving factors

The rapid growth of the big health industry is driven by multiple factors and can grow in the future.

1. The expansion of aging in China and the United States and the widespread use of new health care products are positive factors for the long-term growth of the health industry.

● The population aged 65 and over in the United States: 14% (42 million) of the national population in 2016 and 19% (63 million) in 2020;

● China's population aged 65 and over: In 2016, it accounted for 16% of the country's population (222 million), and in 2020 it is expected to be 17% (248 million).

2, the speed of basic scientific progress is unprecedented, medical discoveries and innovations emerge one after another, creating near-infinite potential for the big health industry. It also promotes the emergence of new, high-value, disruptive treatments, diagnostic instruments, and medical devices.

3. The biopharmaceutical company's product line has the magical effect of delaying and even curing the disease, satisfying a large number of unmet clinical needs. Such as hepatitis C, tumor immunotherapy, rare genetic diseases.

4. Investment M&A activities in the life sciences have increased the potential value of new drugs and new device R&D companies.

two. Why choose China?

(1) China's big health industry: rapid development momentum

China's life sciences and health industry market scale ranked 9th in the world in 2007, and has now jumped to the second place in the world; while maintaining a rapid growth of 9-15% per year, it is expected to reach the world's first place in 2020.

深度解析:中国大健康领域投资趋势与机遇

Blood And Sample Collector

Guangdong Widinlsa International Co.Ltd , https://www.guangdongwidinlsa.com